ZA201108571B - Use of pufas to treat nerve damage - Google Patents

Use of pufas to treat nerve damage

Info

Publication number
ZA201108571B
ZA201108571B ZA2011/08571A ZA201108571A ZA201108571B ZA 201108571 B ZA201108571 B ZA 201108571B ZA 2011/08571 A ZA2011/08571 A ZA 2011/08571A ZA 201108571 A ZA201108571 A ZA 201108571A ZA 201108571 B ZA201108571 B ZA 201108571B
Authority
ZA
South Africa
Prior art keywords
pufas
nerve damage
treat nerve
treat
damage
Prior art date
Application number
ZA2011/08571A
Other languages
English (en)
Inventor
Norman Cameron
Angus Morrison
Phil Knowles
Adam Kelliher
Original Assignee
Equateq Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Equateq Ltd filed Critical Equateq Ltd
Publication of ZA201108571B publication Critical patent/ZA201108571B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2011/08571A 2009-05-01 2011-11-22 Use of pufas to treat nerve damage ZA201108571B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0907601.9A GB0907601D0 (en) 2009-05-01 2009-05-01 Novel methods
PCT/GB2010/000817 WO2010125330A1 (en) 2009-05-01 2010-04-22 Use of pufas to treat nerve damage

Publications (1)

Publication Number Publication Date
ZA201108571B true ZA201108571B (en) 2013-01-30

Family

ID=40792178

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/08571A ZA201108571B (en) 2009-05-01 2011-11-22 Use of pufas to treat nerve damage

Country Status (14)

Country Link
US (1) US20120122982A1 (https=)
EP (1) EP2424519A1 (https=)
JP (1) JP5608220B2 (https=)
KR (1) KR101664518B1 (https=)
CN (1) CN102448453B (https=)
AU (1) AU2010243368C1 (https=)
BR (1) BRPI1009922A2 (https=)
CA (1) CA2762009C (https=)
GB (1) GB0907601D0 (https=)
MX (1) MX2011011615A (https=)
NZ (1) NZ596674A (https=)
SG (1) SG175848A1 (https=)
WO (1) WO2010125330A1 (https=)
ZA (1) ZA201108571B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
EP3068757B1 (en) * 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065393B1 (en) * 1981-05-12 1984-12-27 Imperial Chemical Industries Plc Pyrrole derivatives
US4532254A (en) * 1983-03-17 1985-07-30 Kaken Pharmaceutical Co., Ltd. Inhibitor of aldose reductase
EP0335979A4 (en) * 1987-09-16 1992-02-26 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
PT707487E (pt) * 1993-06-09 2004-08-31 Martek Biosciences Corp Metodos e composicoes farmaceuticas uteis no tratamento de disturbios neurologicos
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
US6107349A (en) * 1998-04-16 2000-08-22 Mantynen; Philip R. Method and composition for treating psoriasis
GB9827391D0 (en) * 1998-12-11 1999-02-03 Fundation O N C F Aldose reductase inhibitors and pharmaceutical compositions
CA2304906A1 (en) * 2000-04-07 2001-10-07 1411198 Ontario Limited 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
WO2001083427A1 (en) * 2000-04-28 2001-11-08 Sankyo Company, Limited PPARη MODULATORS
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
WO2002101392A2 (en) * 2001-06-08 2002-12-19 Xenon Genetics, Inc. Methods for treating disorders of the nervous and reproductive systems
US7410955B2 (en) * 2002-03-25 2008-08-12 Biosynergen, Inc. Therapeutic use of agonist ligands specific to G2A receptor
JP4972745B2 (ja) * 2005-06-22 2012-07-11 国立大学法人群馬大学 Ｇタンパク質共役型受容体ｇ２ａの作動薬、及びｇ２ａ活性調節薬のスクリーニング方法
JP5366211B2 (ja) * 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物

Also Published As

Publication number Publication date
JP5608220B2 (ja) 2014-10-15
CA2762009A1 (en) 2010-11-04
CN102448453B (zh) 2016-07-06
KR101664518B1 (ko) 2016-10-11
WO2010125330A1 (en) 2010-11-04
JP2012525362A (ja) 2012-10-22
MX2011011615A (es) 2012-01-27
SG175848A1 (en) 2011-12-29
CN102448453A (zh) 2012-05-09
KR20120023729A (ko) 2012-03-13
US20120122982A1 (en) 2012-05-17
EP2424519A1 (en) 2012-03-07
AU2010243368C1 (en) 2014-04-03
AU2010243368B2 (en) 2013-10-24
GB0907601D0 (en) 2009-06-10
BRPI1009922A2 (pt) 2016-03-15
NZ596674A (en) 2013-09-27
AU2010243368A1 (en) 2011-12-15
CA2762009C (en) 2016-11-22

Similar Documents

Publication Publication Date Title
ZA201304280B (en) Treatment of jak2-mediated conditions
SMT201900619T1 (it) Uso di pufa per la cura di un'infiammazione cutanea
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL226401A0 (en) Methods for treating disorders related to @fgfBA
IL217777A0 (en) Methods for treatment of pain
IL221476A0 (en) Methods and compositions to treat hemorrhagic conditions of the brain
GB0915515D0 (en) Treatment of vasculoproliferative conditions
IL214664A0 (en) Methods of treating hair related conditions
PT2435825E (pt) Métodos para o tratamento de doenças
EP2675460A4 (en) TREATMENT OF FAT TISSUE UNDER CHIN
GB0919097D0 (en) Treatment of hard surfaces
GB0902040D0 (en) Composition for treatment of skin
IL206491A0 (en) Treatment of produce
IL225896A0 (en) Treatment of mecp-2 related disorders
IL256026B (en) Treatment methods
GB0901456D0 (en) Treatment of psoriasis
ZA201102173B (en) Treatment of water
ZA201202213B (en) Treatment of minerals
ZA201107948B (en) Treatment of water
EP2473193A4 (en) METHOD OF NERVE TISSUE MANIPULATION
ZA201108571B (en) Use of pufas to treat nerve damage
ZA201200645B (en) Use of monochlorourea to treat industrial waters
GB0914839D0 (en) Treatment of oil
IL200753A0 (en) Treatment of psoriasis
ZA201408057B (en) Compositions and methods for the treatment of moderate to severe pain